Interfering with cancer: A brief outline of advances in RNA interference in oncology

Tumor Biology

Volumn 25, Issue 5-6, 2004, Pages 329-336

  Rye, P D ^a   Stigbrand, T ^b  

^a Axis Shield ASA   (Norway)

^b UMEÅ UNIVERSITY   (Sweden)

Author keywords

Molecular oncology; RNA interference

Indexed keywords

RNA;

GENE FUSION; GENE REPRESSION; GENE TARGETING; GENE THERAPY; NONHUMAN; ONCOLOGY; PRIORITY JOURNAL; REVIEW; RNA INTERFERENCE;

EID: 11444265150     PISSN: 10104283     EISSN: None     Source Type: Journal    
DOI: 10.1159/000081403     Document Type: Review

References (64)

1. Parkin DM, Pisani P, Ferlay J: Global cancer statistics. CA Cancer J Clin 1999;49:33-64.
2. Lim SJ, Gutierrez-Puente Y, Tari AM: N-(4-hydroxyphenyl)-retinamide selectively increases all-trans retinoic acid inhibitory effects in HER2/NEU-overexpressing breast cancer cells. Tumor Biol 2002;23:279-286.
3. Elliott MJ, Farmer MR, Atienza C Jr, Stilwell A, Dong YB, Yang HL, Wong SL, McMasters KM: E2F-1 gene therapy induces apoptosis and increases chemosensitivity in human pancreatic carcinoma cells. Tumor Biol 2002;23:76-86.
4. Elliott MJ, Baker JD, Dong YB, Yang HL, Gleason JF Jr, McMasters KM: Inhibition of cyclin A kinase activity in E2F-1 chemogene therapy of colon cancer. Tumor Biol 2002;23:324-336.
5. McKenna WG, Muschel RJ: Targeting tumor cells by enhancing radiation sensitivity. Genes Chromosomes Cancer 2003;38:330-338.
6. Yeh JJ, Hsu WH, Huang WT, Wang JJ, Ho ST, Kao A: Technetium-99m tetrofosmin SPECT predicts chemotherapy response in small cell lung cancer. Tumor Biol 2003;24:151-155.
7. Dorvillius M, Garambois V, Pourquier D, Gutowski M, Rouanet P, Mani JC, Pugniere M, Hynes NE, Pelegrin A: Targeting of human breast cancer by a bispecific antibody directed against two tumour-associated antigens: ErbB-2 and carcinoembryonic antigen. Tumor Biol 2002;23:337-347.
8. Chester K, Pedley B, Tolner B, Violet J, Mayer A, Sharma S, Boxer G, Green A, Nagl S, Begent R: Engineering antibodies for clinical applications in cancer. Tumor Biol 2004;25:91-98.
9. Selbo PK, Hogset A, Prasmickaite L, Berg K: Photochemical internalisation: A novel drug delivery system. Tumor Biol 2002;23:103-112.
10. Fenchel S, Boll DT, Lewin JS: Intraoperative MR imaging. Magn Reson Imaging Clin N Am 2003;11:431-447.
11. Curiel DT, Douglas JT (eds): Cancer Gene Therapy. Totowa, Humana Press, 2005.
12. Chi KN, Gleave ME: Antisense approaches in prostate cancer. Expert Opin Biol Ther 2004;4:927-936.
13. Holmlund JT: Applying antisense technology: Affinitak and other antisense oligonucleotides in clinical development. Ann NY Acad Sci 2003;1002:244-251.
14. Abaza MS, Al-Attiyah RJ, Al-Saffar AM, Al-Sawan SM, Moussa NM: Antisense oligodeoxynucleotide directed against c-myb has anticancer activity and potentiates the antiproliferative effect of conventional anticancer drugs acting by different mechanisms in human colorectal cancer cells. Tumor Biol 2003;24:241-257.
15. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC: Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998;391:806-811.
16. Liu J, Carmell MA, Rivas FV, Marsden CG, Thomson JM, Song JJ, Hammond SM, Joshua-Tor L, Hannon GJ: Argonaute2 is the catalytic engine of mammalian RNAi. Science 2004; 305:1437-1441. Epub Jul 29.
17. Song JJ, Smith SK, Hannon GJ, Joshua-Tor L: Crystal structure of argonaute and its implications for RISC slicer activity. Science 2004; 305:1434-1437. Epub Jul 29.
18. Lee NS, Dohjima T, Bauer G, Li H, Li MJ, Ehsani A, Salvaterra P, Rossi J: Expression of small interfering RNAs targeted against HIV-1 rev transcripts in human cells. Nat Biotechnol 2002;20:500-505.
19. Paul CP, Good PD, Winer I, Engelke DR: Effective expression of small interfering RNA in human cells. Nat Biotechnol 2002;20:505-508.
20. Sui G, Soohoo C, Affar el B, Gay F, Shi Y, Forrester WC, Shi Y: A DNA vector-based RNAi technology to suppress gene expression in mammalian cells. Proc Natl Acad Sci USA 2002;99:5515-5520.
21. Paddison PJ, Caudy AA, Bernstein E, Hannon GJ, Conklin DS: Short hairpin RNAs (shRNAs) induce sequence-specific silencing in mammalian cells. Genes Dev 2002;16:948-958.
22. Brummelkamp TR, Bernards R, Agami R: A system for stable expression of short interfering RNAs in mammalian cells. Science 2002;296:550-553.
23. Shen C, Buck AK, Liu X, Winkler M, Reske SN: Gene silencing by adenovirus-delivered siRNA. FEBS Lett 2003;539:111-114.
24. Berns K, Hijmans EM, Mullenders J, Brummelkamp TR, Velds A, Heimerikx M, Kerkhoven RM, Madiredjo M, Nijkamp W, Weigelt B, Agami R, Ge W, Cavet G, Linsley PS, Beijersbergen RL, Bernards R: A large-scale RNAi screen in human cells identifies new components of the p53 pathway. Nature 2004;428:431-437.
25. Chen J, Wall NR, Kocher K, Duclos N, Fabbro D, Neuberg D, Griffin JD, Shi Y, Gilliland DG: Stable expression of small interfering RNA sensitizes TEL-PDGFbetaR to inhibition with imatinib or rapamycin. J Clin Invest 2004;113:1784-1791.
26. Peng Y, Zhang Q, Nagasawa H, Okayasu R, Liber HL, Bedford JS: Silencing expression of the catalytic subunit of DNA-dependent protein kinase by small interfering RNA sensitizes human cells for radiation-induced chromosome damage, cell killing, and mutation. Cancer Res 2002;62:6400-6404.
27. Brummelkamp TR, Bernards R, Agami R: Stable suppression of tumorigenicity by virus-mediated RNA interference. Cancer Cell 2002;2:243-247.
28. Okada H, Mak TW: Pathways of apoptotic and non-apoptotic death in tumour cells. Nat Rev Cancer 2004;4:592-603.
29. Ikeguchi M, Yamaguchi K, Kaibara N: Survivin gene expression positively correlates with proliferative activity of cancer cells in esophageal cancer. Tumor Biol 2003;24:40-45.
30. Williams NS, Gaynor RB, Scoggin S, Verma U, Gokaslan T, Simmang C, Fleming J, Tavana D, Frenkel E, Becerra C: Identification and validation of genes involved in the pathogenesis of colorectal cancer using cDNA microarrays and RNA interference. Clin Cancer Res 2003;9:931-946.
31. Ling X, Li F: Silencing of antiapoptotic survivin gene by multiple approaches of RNA interference technology. Biotechniques 2004;36:450-454, 456-460.
32. Wilda M, Fuchs U, Wossmann W, Borkhardt A: Killing of leukemic cells with a BCR/ABL fusion gene by RNA interference (RNAi). Oncogene 2002;21:5716-5724.
33. Dohjima T, Lee NS, Li H, Ohno T, Rossi JJ: Small interfering RNAs expressed from a Pol III promoter suppresses the EWS/Fli-1 transcript in a Ewing sarcoma cell line. Mol Ther 2003;7:811-816.
34. Zamore PD, Tuschl T, Sharp PA, Bartel DP: RNAi: Double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals. Cell 2000;101:25-33.
35. Bernstein E, Caudy AA, Hammond SM, Hannon GJ: Role for a bidentate ribonuclease in the initiation step of RNA interference. Nature 2001;409:363-366.
36. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T: Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001;411:494-498.
37. Paul CP, Good PD, Winer I, Engelke DR: Effective expression of small interfering RNA in human cells. Nat Biotechnol 2002;20:505-508.
38. Song E, Lee SK, Wang J, Ince N, Ouyang N, Min J, Chen J, Shankar P, Lieberman J: RNA interference targeting Fas protects mice from fulminant hepatitis. Nat Med 2003;9:347-351.
39. Butz K, Ristriani T, Hengstermann A, Denk C, Scheffner M, Hoppe-Seyler F. siRNA targeting of the viral E6 oncogene efficiently kills human papillomavirus-positive cancer cells. Oncogene 2003;22:5938-5945.
40. Yoshinouchi M, Yamada T, Kizaki M, Fen J, Koseki T, Ikeda Y, Nishihara T, Yamato K: In vitro and in vivo growth suppression of human papillomavirus 16-positive cervical cancer cells by E6 siRNA. Mol Ther 2003;8:762-768.
41. Jiang M, Milner J: Selective silencing of viral gene expression in HPV-positive human cervical carcinoma cells treated with siRNA, a primer of RNA interference. Oncogene 2002;21:6041-6048.
42. Brummelkamp TR, Bernards R, Agami R: Stable suppression of tumorigenicity by virus-mediated RNA interference. Cancer Cell 2002;2:243-247.
43. Kawasaki H, Taira K: Short hairpin type of dsRNAs that are controlled by tRNA(Val) promoter significantly induce RNAi-mediated gene silencing in the cytoplasm of human cells. Nucleic Acids Res 2003;31:700-707.
44. Duursma AM, Agami R: Ras interference as cancer therapy. Semin Cancer Biol 2003;13:267-273.
45. Hemann MT, Fridman JS, Zilfou JT, Hernando E, Paddison PJ, Cordon-Cardo C, Hannon GJ, Lowe SW: An epi-allelic series of p53 hypomorphs created by stable RNAi produces distinct tumor phenotypes in vivo. Nat Genet 2003;33:396-400.
46. Yang G, Cai KQ, Thompson-Lanza JA, Bast RC Jr, Liu J: Inhibition of breast and ovarian tumor growth through multiple signaling pathways by using retrovirus-mediated small interfering RNA against Her-2/neu gene expression. J Biol Chem 2004;279:4339-4345.
47. Choudhury A, Charo J, Parapuram SK, Hunt RC, Hunt DM, Seliger B, Kiessling R: Small interfering RNA (siRNA) inhibits the expression of the Her2/neu gene, upregulates HLA class I and induces apoptosis of Her2/neu positive tumor cell lines. Int J Cancer 2004;108:71-77.
48. Kappler M, Bache M, Bartel F, Kotzsch M, Panian M, Wurl P, Blumke K, Schmidt H, Meye A, Taubert H: Knockdown of survivin expression by small interfering RNA reduces the clonogenic survival of human sarcoma cell lines independently of p53. Cancer Gene Ther 2004;11:186-193.
49. Williams NS, Gaynor RB, Scoggin S, Verma U, Gokaslan T, Simmang C, Fleming J, Tavana D, Frenkel E, Becerra C: Identification and validation of genes involved in the pathogenesis of colorectal cancer using cDNA microarrays and RNA interference. Clin Cancer Res 2003;9:931-946.
50. Ling X, Li F: Silencing of antiapoptotic survivin gene by multiple approaches of RNA interference technology. Biotechniques 2004;36:450-454, 456-460.
51. Bhoumik A, Jones N, Ronai Z: Transcriptional switch by activating transcription factor 2-derived peptide sensitizes melanoma cells to apoptosis and inhibits their tumorigenicity. Proc Natl Acad Sci USA 2004;101:4222-4227.
52. Menendez JA, Vellon L, Mehmi I, Oza BP, Ropero S, Colomer R, Lupu R: Inhibition of fatty acid synthase (FAS) suppresses HER2/ neu (erbB-2) oncogene overexpression in cancer cells. Proc Natl Acad Sci USA 2004;101:10715-10720.
53. Lee RC, Feinbaum RL, Ambros V: The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 1993;75:843-854.
54. Xia H, Mao Q, Paulson HL, Davidson BL: siRNA-mediated gene silencing in vitro and in vivo. Nat Biotechnol 2002;20:1006-1010.
55. Lima RT, Martins LM, Guimaraes JE, Sambade C, Vasconcelos MH: Specific downregulation of bcl-2 and xIAP by RNAi enhances the effects of chemotherapeutic agents in MCF-7 human breast cancer cells. Cancer Gene Ther 2004;11:309-316.
56. Salvi A, Arici B, De Petro G, Barlati S: Small interfering RNA urokinase silencing inhibits invasion and migration of human hepatocellular carcinoma cells. Mol Cancer Ther 2004;3:671-678.
57. Wang D, Luo M, Kelley MR: Human apurinic endonuclease 1 (APE1) expression and prognostic significance in osteosarcoma: Enhanced sensitivity of osteosarcoma to DNA damaging agents using silencing RNA APE1 expression inhibition. Mol Cancer Ther 2004;3:679-686.
58. Wang Z, Li Y, Liu ET, Yu Q: Susceptibility to cell death induced by blockade of MAPK pathway in human colorectal cancer cells carrying Ras mutations is dependent on p53 status. Biochem Biophys Res Commun 2004;322:609-613.
59. Chen CZ, Li L, Lodish HF, Bartel DP: Micro RNAs modulate hematopoietic lineage differentiation. Science 2004;303:83-86.
60. Jakubowiak A, Pouponnot C, Berguido F, et al: Inhibition of the transforming growth factor beta 1 signaling pathway by the AML1/ETO leukemia-associated fusion protein. J Biol Chem 2000;275:40282-40287.
61. Pabst T, Mueller BU, Zhang P, et al: Dominant negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBP alpha) in acute myeloid leukemia. Nat Genet 2001;27:263-270.
62. Caplen NJ: Gene therapy progress and prospects. Downregulating gene expression: The impact of RNA interference. Gene Therapy 2004;11:1241-1248.
63. Wang Y, Engels IH, Knee DA, Nasoff M, Deveraux QL, Quon KC: Synthetic lethal targeting of MYC by activation of the DR5 death receptor pathway. Cancer Cell 2004;5:501-512.
64. Hemann MT, Fridman JS, Zilfou JT, Hernando E, Paddison PJ, Cordon-Cardo C, Hannon GJ, Lowe SW: An epi-allelic series of p53 hypomorphs created by stable RNAi produces distinct tumor phenotypes in vivo. Nat Genet 2003;33:396-400.